EBO 0.00% $36.90 ebos group limited ordinary shares

Ann: ANNREP: EBO: EBOS Listing of NZSX Waivers gr

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. lightbulb Created with Sketch. 2
    • Release Date: 20/09/13 13:18
    • Summary: ANNREP: EBO: EBOS Listing of NZSX Waivers granted
    • Price Sensitive: No
    • Download Document  8.19KB
    					EBO
    20/09/2013 11:18
    ANNREP
    
    REL: 1118 HRS Ebos Group Limited
    
    ANNREP: EBO: EBOS Listing of NZSX Waivers granted
    
    20 September 2013
    
    NZSX WAIVERS
    In accordance with NZSX Listing Rule 10.5.5(f) the Company advises the
    following NZSX waivers have been granted.
    During the twelve (12) month period ending on 23 July 2013 the Company
    applied to NZSX for waivers from NZSX Listing Rules 7.10.5, 9.2.1, 7.12.2 and
    7.10.2, all of which were granted.
    BACKGROUND
    1 On 28 May 2013 the Company entered into an agreement to purchase the entire
    issued share capital of Zuellig Healthcare Holdings Australia Pty Limited
    (Symbion) from Symbion Holdings Pte Limited (the Vendor).  The purchase price
    for Symbion of $865 million (Purchase Price) was satisfied through the issue
    of fully paid ordinary shares in the Company to the Vendor having a value of
    approximately $498 million (Consideration Shares) and a cash payment of
    approximately $367 million (Consideration Cash).  The issue of the
    Consideration Shares resulted in the Vendor and associates holding 40% of the
    total issues shares in the Company (together the Transaction).
    2 The Company funded the Consideration Cash by:
    2.1 completing an underwritten placement of EBOS ordinary shares worth
    approximately $90 million to new and existing institutional investors (the
    Placement);
    2.2 undertaking an underwritten 7 for 20 pro-rata renounceable rights offer
    worth approximately $149 million (the Entitlement Offer); and
    2.3 additional debt facilities of approximately $140 million.
    3 The Company wished to offer it's shareholders who accepted their
    Entitlement Offer entitlement in full the option to apply for additional
    rights not taken up by other shareholders by way of an oversubscription
    facility (Oversubscription Facility), necessitating a waiver from the
    provisions of NZSX Listing Rule 7.10.5 (Rule 7.10.5).
    4 The Transaction was a material transaction under NZSX Listing Rule 9.2.1
    (Rule 9.2.1) due to it being a purchase of assets having an Aggregate Net
    Value in excess of 10% of the Company's then Average Market Capitalisation of
    approximately $518 million.
    
    5 Rule 9.2.1 requires that the Company as an Issuer shall not enter into a
    Material Transaction if a Related Party is a party to at least one of a
    related series of transactions which form part of the Material Transaction
    unless the transaction associated to the Related Party is approved by an
    ordinary resolution of the Company.  As the Placement and Entitlement Offer
    formed part of the Transaction, each was considered part of a related series
    of transactions.
    6 Two companies that are Related Parties of of the Company wished to
    participate in the Placement and act as sub-underwriters to the Entitlement
    Offer. Whyte Adder No 3 Limited and Herpa Properties Limited (the Related
    Companies) are both a Related Party under Rule 9.2.3(a) as two directors of
    the Related Companies, Mr Peter Kraus and Mr Barry Wallace, are both
    directors of EBOS.  Together the Related Companies then held 8.43% of the
    Company's shares on issue.  The Placement and sub-underwriting formed part of
    the related series of transactions of the Material Transaction, being the
    Transaction.
    7 In order to meet the timeframe of the Transaction, the Company needed to
    set the closing date for applications under the Entitlement Offer as ten
    Business Days after the mailing of the letters of entitlement instead of the
    twelve Business Days required by NZSX Listing Rule 7.10.2 (Rule 7.10.2).
    8 Prior to the Placement, Entitlement Offer and issue of Consideration
    Shares, the Company undertook a bonus issue of it's shares (Bonus Issue) to
    allocate imputation credits to the Company's shareholders.  The Bonus Issue
    resulted in the Company's shareholders receiving two new EBOS shares for
    every 53 EBOS shares held at the Bonus Issue Record Date of 6 June 2013.
    9 The Company approached NZX Regulation (NZXR) for a waiver from Rules
    7.10.5, 9.2.1 and 7.10.2 in respect of the Transaction, and a waiver from
    Rule 7.12.2 in respect of the Bonus Issue.
    10 Waivers applied for and granted:
    10.1 Listing Rule 7.10.5
    The Company applied to NZXR for a waiver from the requirements in Rule 7.10.5
    in order that the Entitlement Offer could include the Oversubscription
    Facility.
    NZXR granted the waiver subject to the following conditions:
    (a) to the extent available, and pro rated to the extent not, allocations
    under the Oversubscription Facility were to be made to any shareholder
    participating in the Oversubscription Facility who would otherwise hold less
    than a minimum holding after the Entitlement Offer to the extent to allow
    them to hold a minimum holding; and
    (b) in respect of any remaining rights, in the event that demand for the
    Entitlement Offer exceeded supply, participants were to be scaled on a pro
    rata basis in accordance with their shareholding at the Record Date for their
    entitlement.
    10.2 Listing Rule 9.2.1
    The Company applied to NZXR for a waiver from Rule 9.2.1 so that the Related
    Companies could participate in the Placement and act as sub-underwriters to
    the Entitlement Offer without obtaining shareholder approval.
    NZXR granted the waiver subject to the following conditions:
    (a) the terms and conditions on which the Related Companies participate in
    the Placement and act as sub-underwriters of the Entitlement Offer were to be
    identical to those offered to the other parties who were participating in the
    Placement and acting as sub-underwriters;
    (b) the directors of the Company, other than Mr Kraus and Mr Wallace, certify
    to NZXR that Mr Kraus and Mr Wallace had no part in the negotiation of the
    terms of participation in the Placement or as sub-underwriters;
    (c) Mr Kraus and Mr Wallace abstain from, and do not participate in any
    discussions or approval of the Placement allocations;
    (d) the Notice of Meeting in respect of the approval of the acquisition of
    Symbion clearly discloses the participation of the Related Companies in the
    Placement and as sub-underwriters of the Entitlement Offer; and
    (e) the Notice of Meeting in respect of the approval of the acquisition of
    Symbion clearly discloses the Related Companies are considered Related
    Parties to the Symbion Transaction in respect of Rule 9.2.1.
    10.3 Listing Rule 7.12.2
    The Company applied to NZXR for a waiver from Rule 7.12.2 to permit the Bonus
    Issue Record Date to be six Business Days after the announcement of the Bonus
    Issue rather than the stipulated ten Business Days.
    NZXR granted the waiver subject to the following conditions:
    (a) The Company releases information on the Bonus Issue in the form required
    by Rule 7.12.2 on the day of announcement of the Transaction, Wednesday 29
    May 2013; and
    (b) The Record Date for the Bonus Issue is 6 June 2013.
    The conditions of the waiver from Rule 7.12.2 required the Company to provide
    the market six Business Days' notice of the Bonus Issue.  Within these six
    Business Days the market would have at least one day, 31 May 2013, where
    trading can occur in order for those who wished to move on or off the Company
    share register before the Bonus Issue.
    10.4 Listing Rule 7.10.2
    The Company applied to NZXR for a waiver from Rule 7.10.2 so that it could
    set the closing date for applications under the Entitlement Offer as ten
    Business Days after the mailing of letters of entitlement instead of the
    twelve Business Days required by Rule 7.10.2.
    NZXR granted the waiver subject to the following conditions:
    (a) the prospectus and acceptance form contain prominent statements
    encouraging shareholders to accept early and utilise direct credit as a
    payment option;
    (b) the prospectus be posted as soon as practicable after the shareholder
    meeting on 14 June 2013 and in any event before the end of 17 June 2013;
    (c) The Company files an appendix 7 confirming the offer timetable as soon as
    a waiver is finalised and release to the market copy of the prospectus, and
    post a copy on its website, promptly after registration; and
    (d) letters of entitlement and the prospectus be sent by fast post to those
    outside Auckland (being the place the Company's share registrar/mail house
    are located).
    11 A complete copy of the waivers referred to above can be found at
    www.ebos.co.nz or at www.nzx.com under the EBO code.
    
    Yours faithfully
    EBOS GROUP LIMITED
    
    Dennis Doherty
    Chief Financial Officer
    End CA:00241370 For:EBO    Type:ANNREP     Time:2013-09-20 11:18:34
    				
 
watchlist Created with Sketch. Add EBO (NZSX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.